Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-176 in Healthy Adults

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-176 in Healthy Adults

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SAB 176 (Primary)
  • Indications Influenza A virus H1N1 subtype; Influenza A virus infections; Influenza B virus infections
  • Focus Adverse reactions
  • Sponsors SAB BIO

    • Most Recent Events

    • 20 Jun 2024 According to a SAB Biotherapeutics media release, company name changed from SAB Biotherapeutics to SAB BIO.
    • 25 Mar 2024 According to SAB Biotherapeutics media release, the company announced that the Navy Medical Research Command (NMRC) is moving forward with this study. The NMRC Clinical Trials Center, located in Bethesda, Maryland, will be conducting this PK study under the leadership of Cmdr. Nehkonti Adams, Director, NMRC Clinical Trials Center.
    • 04 May 2023 According to SAB Biotherapeutics media release, data from this study presented at the AVG conference

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top